title: Biologics Will Pump Up the Vasculitis Market.
abstract: Vasculitis, a group of heterogeneous disorders characterized by inflammation and necrosis of the blood vessels, has but one treatment approved by the Food and Drug Administration. However, six novel biologic candidates are in late-stage development.
authors.forename: Chris
authors.initials: C
authors.lastname: Fellner